Forge Life Science Partners leads $50 million Series B financing Lead program is an oral, selective IGF-1R inhibitor for thyroid eye disease SAN DIEGO--(BUSINESS WIRE)-- Khartis Therapeutics , a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced today that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria

- All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive data could support expansion of CNT201 into Peyronie's disease and cellulite Aug. 17, 2026 -- Connext, a specialty therapeutics company focused on developing innovative therapies for significant unmet medical needs, today announced that it has completed enrollment in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating CNT201 for t

Aug. 17, 2026 -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug UGN-103 (mitomycin) for intravesical solution. UGN-103 is a next-generation mitomycin formulation being developed for the treatment of adults with recurrent low-grade intermediate-r

Shortly after inking a deal to expand its rights to CD38-targeting antibody felzartamab across the globe, Biogen has won approval for the drug's use to treat multiple myeloma (MM) in China. China's National Medical Products Administration (NMPA) on Thursday approved felzartamab in combination with lenalidomide and dexamethasone to treat adults with MM who have received at least one prior line of therapy, according to a report from China Daily. Biogen initially gained ex-China global rights to

Redx Pharma is making its second attempt to go public in a reverse merger, announcing Monday that it will combine with Skye Bioscience to create a new company that will trade on NASDAQ as Fibrx Therapeutics. The deal, expected to close in the fourth quarter, comes more than three years after Redx first tried to combine with another drugmaker. In early 2023, it moved to merge with Jounce Therapeutics, but Concentra Biosciences countered with a takeover bid, ultimately winning out over Redx. Red

Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported functional recovery Aug. 14, 2026 -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced new preclinical tissue-analysis results that provide additional biological supp

A novel diagnostic agent to identify patients with tau neurofibrillary tangles (NFTs), including NFTs isolated to the medial temporal lobe Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, also previously referred to as MK-6240), a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to i

Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb’s targeted protein degradation platform PRINCETON, N.J.---Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has appr

Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. Aug. 10, 2026 -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial closing, with participation from Eli Lilly and Company ("Lilly") and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Direc

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment Aug. 10, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up t